Log in to search using one of your social media accounts:

 

Facial fracture-associated blindness - B éogo R, Coulibaly TA, Dolo MT, Traoré I, Ouattara B, Diallo JW.
INTRODUCTION: Yet uncommon, blindness is a potential associated injury of facial fractures. METHODS: Epidemiology, mechanisms, fracture types, and outcome of facial fractures-associated blindness in a 10-year period are retrospectively reviewed. ... (Source: SafetyLit)
Source: SafetyLit - February 19, 2018 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Eritrea:Commendable Ophthalmologic Activities in Preventing Blindness
[Shabait] Keren -The Ophthalmology Department in Keren Hospital is conducting commendable eye diseases treatment activities, particularly eye surgeries, Mr. Kahsai Sium, an expert in eye treatment at the hospital reported. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - February 19, 2018 Category: African Health Source Type: news

Traumatic cataract in children in Eastern China: Shanghai Pediatric Cataract Study - Du Y, He W, Sun X, Lu Y, Zhu X.
Traumatic cataract is a main cause of visual impairment in pediatric populations and is preventable. Awareness of the causes and consequences of pediatric eye trauma play roles in health education and prevention of blindness. We conducted a retrospective c... (Source: SafetyLit)
Source: SafetyLit - February 17, 2018 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news

Cameroon:Blindness, Diabetic Retinopathy - Women Mostly Affected!
[Cameroon Tribune] This is one of the results of an investigation carried out in Yaounde by an international NGO, "Sightsavers and Partners." (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - February 16, 2018 Category: African Health Source Type: news

Medical News Today: What causes a buildup of pressure behind the eyes?
In this article, we look at reasons for feelings of pressure behind the eye, including a migraine or sinus infection. When should you see a doctor? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 16, 2018 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news

NIH solicits next-generation retina organoids in prize competition
(NIH/National Eye Institute) A competition for radical ideas in the fight against blindness will move to its next phase by challenging participants to build functioning human retina prototypes. The National Eye Institute (NEI) 3-D Retina Organoid Challenge (NEI 3-D ROC 2020) is a $1-million federal prize competition designed to generate lab-grown human retinas from stem cells. Organoids developed for the competition will mimic the structure, organization, and function of the human retina. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 14, 2018 Category: International Medicine & Public Health Source Type: news

Could gene editing fight the AIDS crisis?
Experts say gene editing, which has been FDA-approved to treat cancer and blindness, could also be used to treat HIV and AIDS. (Source: the Mail online | Health)
Source: the Mail online | Health - February 13, 2018 Category: Consumer Health News Source Type: news

Medical News Today: How do you get rid of puffy eyes?
A look at periorbital edema, a condition where swelling around the eyes causes them to appear puffy. Included is detail on diagnosis and the outlook. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 12, 2018 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news

Medical News Today: Everything you need to know about papilledema
A look at papilledema, a condition where the optic nerve becomes swollen. Included is detail on the outlook and how to get a diagnosis. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 9, 2018 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news

New discovery offers hope of protecting premature babies from blindness
(University of Gothenburg) Now there is hope of a new way to protect extremely premature babies from impaired vision or blindness resulting from the eye disease retinopathy of prematurity (ROP). A study at Sahlgrenska Academy published in JAMA Ophthalmology points to a clear link between ROP and low levels of the fatty acid arachidonic acid, measured in children's blood. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 9, 2018 Category: Biology Source Type: news

Diabetes Patients May Be Injecting Disintegrated Insulin, Experts Say
(TRENTON, N.J.) — Preliminary research suggesting that some diabetes patients may be injecting medicine that has partially disintegrated is causing concern even as serious questions are raised about the research itself. The study author, a pharmacist, bought vials of insulin at a number of pharmacies and found that on average the vials had less than half of what was listed on the label and none met a minimum standard. The study tested just 18 vials of insulin — far too few to be definitive — and questions have been raised about the methods used to test the insulin. Insulin makers, patient advocate groups ...
Source: TIME: Health - February 7, 2018 Category: Consumer Health News Authors: Linda A. Johnson / AP Tags: Uncategorized APH diabetes healthytime onetime Source Type: news

Bausch + Lomb and The Organization, Prevent Blindness, Encourage...
Campaign Encourages People to Share their #WhyEyeFight Stories to Bring Awareness to this Progressive Eye Disease(PRWeb February 06, 2018)Read the full story at http://www.prweb.com/releases/2018/02/prweb15170100.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 6, 2018 Category: Pharmaceuticals Source Type: news

Second Sight touts 1st-in-human Orion cortical implant
Second Sight Medical (NSDQ:EYES) today announced the first trial implantation of its Orion cortical visual prosthesis system and updated on implantations of its Argus device and enrollment in an upcoming study. The first implantation procedure was performed late last month by Dr. Nader Pouratian at the Ronald Reagan UCLA Medical Center, the Sylmar, Calif.-based company said, as part of an FDA-cleared feasibility trial it won approval to launch last November. The Orion cortical visual prosthesis system is designed to convert images captured by a miniature video camera, mounted on a patient’s glasses, into a ...
Source: Mass Device - February 5, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Second Sight Source Type: news

Business Unusual will Drive Africa ’s Quest to achieve Health Care for All
Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organisation (WHO) pledged his full support for the delivery of universal healthcare within the next five years, one of the pillars of President Uhuru Kenyatta’s Big Four Action plan. Credit: State HouseBy Siddharth Chatterjee and Radhika ShahNAIROBI, Kenya, Feb 5 2018 (IPS)Africa’s quest for health continues to be held back by a combination of factors such as natural disasters and pandemics, prevailing high rates of communicable and rising incidence of non-communicable diseases, sedentary lifestyles, road accidents and greater population mobi...
Source: IPS Inter Press Service - Health - February 5, 2018 Category: International Medicine & Public Health Authors: Siddharth Chatterjee and Radhika Shah Tags: Africa Aid Climate Change Development & Aid Economy & Trade Environment Headlines Health Humanitarian Emergencies Labour Poverty & SDGs TerraViva United Nations Women's Health Source Type: news

Medical News Today: What causes eye boogers?
Eye boogers are mucus, a type of discharge that helps to keep the eyes clean and free of debris. Learn more about eye boogers in this article. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 2, 2018 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news

Spark licenses blindness gene therapy rights outside U.S. to Novartis
(Reuters) - Spark Therapeutics Inc, whose breakthrough gene therapy to treat a rare form of blindness was approved by U.S. regulators in December, has licensed rights to the drug in markets outside the United States to Switzerland-based Novartis AG, it said on Wednesday. (Source: Reuters: Health)
Source: Reuters: Health - January 24, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Novartis strikes $170m deal for ex-US rights to gene therapy for blindness
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - January 24, 2018 Category: Pharmaceuticals Source Type: news

Medical News Today: Five tips for healthy sight
Are you worried about your eyes? We have compiled some top tips to help you maintain healthy sight, boost eye health, and prevent eye-related diseases. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 15, 2018 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news

Medical News Today: What to know about central serous retinopathy
A look at central serous retinopathy, a condition where the retina detaches and causes vision loss. Included is detail on risk factors, and diagnosis. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 13, 2018 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news

Spark's price for Luxturna blindness gene therapy too high: ICER
(Reuters) - The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - January 12, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Spark's planned price for Luxturna gene therapy for rare blindness too high: ICER
(Reuters) - The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - January 12, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Drugmakers see a pricing blueprint in an $850,000 gene therapy
SAN FRANCISCO (Reuters) - Global drugmakers are looking to a tiny biotech's $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines. (Source: Reuters: Health)
Source: Reuters: Health - January 12, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Medical News Today: An introduction to eyes and how they work
The eyes are incredibly complex organs. In this article, we explain their anatomy, how they work, and describe some conditions that affect the eyes. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 12, 2018 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news

KTU students are developing dissolving lenses for glaucoma treatment
(Kaunas University of Technology) Students' team from Kaunas University of Technology (KTU) is working on a development of dissolving contact eye lenses, which can be of great assistance for those suffering from glaucoma. According to statistics, glaucoma is the most common cause of preventable, irreversible blindness -- it is responsible for 12.3 percent of blindness worldwide. It is being estimated that by the year 2020 there will be almost 80 million people in the world suffering from the condition. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 9, 2018 Category: Biology Source Type: news

Inattentional blindness
(Human Factors and Ergonomics Society) Drivers' limited capacity to process the myriad details they absorb could explain why they sometimes fail to avoid crashes with motorcycles. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - January 5, 2018 Category: International Medicine & Public Health Source Type: news

Cost of treating rare genetic blindness: $425,000 per eye
Treatment of a rare, inherited form of blindness will cost $425,000 per eye, the company bringing the therapy to market announced on Wednesday. (Source: Health News - UPI.com)
Source: Health News - UPI.com - January 3, 2018 Category: Consumer Health News Source Type: news

Gene therapy for blindness will cost $850,000  
Drug-maker Spark Therapeutics lowered the cost of its treatment for a rare form of blindness from $1 million, but at $850,000, the drug is still one of the most expensive gene therapies in the world. (Source: the Mail online | Health)
Source: the Mail online | Health - January 3, 2018 Category: Consumer Health News Source Type: news

Spark to charge $850,000 per patient for blindness gene therapy
(Reuters) - Spark Therapeutics Inc said on Wednesday it will charge $850,000 per patient for its breakthrough gene therapy to treat a rare form of blindness, a lower than expected price that the company said reflects patient and insurer concerns about access and cost. (Source: Reuters: Health)
Source: Reuters: Health - January 3, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Gene therapy for type of blindness gets $850K price tag
Drugmaker says it lowered cost of treatment approved by the FDA last month, citing insurer concerns (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - January 3, 2018 Category: Consumer Health News Source Type: news

Spark reveals the price tag for its groundbreaking gene therapy treatment
The Philadelphia company will offer outcomes-based rebates and the possibility for installment payments to help ensure access to the one-time therapy that treats a condition that otherwise leads to blindness. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - January 3, 2018 Category: American Health Authors: John George Source Type: news

Spark Therapeutics' vision-loss gene therapy to cost $850,000 per patient
(Reuters) - Spark Therapeutics Inc said on Wednesday it would charge $850,000 per patient for its gene therapy to treat a rare form of blindness, lesser than analysts' expectation of around $1 million. (Source: Reuters: Health)
Source: Reuters: Health - January 3, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Drug group Spark to charge $850,000 for blindness gene therapy
Luxturna is most expensive treatment on market and price raises affordability questions (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - January 3, 2018 Category: Pharmaceuticals Source Type: news

Spark Therapeutics Sets Price Of Blindness-Curing Gene Therapy At $850,000
A new drug, Luxturna, literally allows blind people to see. It does it by using a virus to insert new genes into patients ’ eyes. This morning, Luxturna’s maker, Spark Therapeutics, is announcing the cost of this medical miracle: $425,000 per eye, or $850,000 a year. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 3, 2018 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:ONCE NASDAQ:IONS NASDAQ:BIIB NASDAQ:ALXN Source Type: news

Spark Therapeutics Sets Price Of Blindness-Treating Gene Therapy At $850,000
A new drug, Luxturna, literally allows blind people to see. It does it by using a virus to insert new genes into patients ’ eyes. This morning, Luxturna’s maker, Spark Therapeutics, is announcing the cost of this medical miracle: $425,000 per eye, or $850,000 a year. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 3, 2018 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:ONCE NASDAQ:IONS NASDAQ:BIIB NASDAQ:ALXN Source Type: news

Scientists advance stem cell therapy for a leading cause of blindness
Researchers made advances toward creating stem cell-derived retinal cells used to treat a leading cause of blindness. (Source: Health News - UPI.com)
Source: Health News - UPI.com - January 2, 2018 Category: Consumer Health News Source Type: news

The 8th Annual Alexander Awards: The Best Tox Reading of 2017
Alexander Gettler Once again, last year’s outstanding examples of long-form journalism dealing with topics related to medical toxicology were dominated by coverage of the opioid crisis, its origins and the resulting carnage. The must-read article of the year was “The Family That Built a Empire of Pain,” Patrick Radden Keefe’s massive history of the Sacklers, one of America’s richest clans, much of whose wealth comes from their ownership of Purdue Pharma and the marketing and distribution of Oxycontin. The article, which appeared in the New Yorker, notes that the clan’s patriarch, Ar...
Source: The Poison Review - January 2, 2018 Category: Toxicology Authors: Leon Gussow Tags: Medical 2017 Alexander awards opioids Purdue Pharma Sackler Source Type: news

NIH discovery brings stem cell therapy for eye disease closer to the clinic
(NIH/National Eye Institute) Scientists at the National Eye Institute report that tiny tube-like protrusions called primary cilia on cells of the retinal pigment epithelium (RPE) -- a layer of cells in the back of the eye -- are essential for the survival of the retina's light-sensing photoreceptors. The discovery has advanced efforts to make stem cell-derived RPE for transplantation into patients with geographic atrophy, otherwise known as dry age-related macular degeneration (AMD), a leading cause of blindness in the US. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 2, 2018 Category: Biology Source Type: news

Medical News Today: What is optic neuritis?
This article looks at the symptoms, treatments, and causes. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 25, 2017 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news

FDA rejects Santen ’s intravitreal uveitis therapy
Shares in Santen Pharmaceutical (OTC:SNPHY) fell -3% today after the company’s U.S. subsidiary said that the FDA rejected the application for its intravitreal sirolimus therapy The company is developing its DE-109 product to treat people with noninfectious uveitis of the posterior segment, which can cause blindness in adults. Get the full story at our sister site, Drug Delivery Business News. The post FDA rejects Santen’s intravitreal uveitis therapy appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - December 21, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Optical/Ophthalmic Pharmaceuticals Regulatory/Compliance Wall Street Beat Santen Pharmaceuticals Source Type: news

FDA approves gene therapy for a type of blindness
The US Food and Drug Administration has approved a gene therapy treatment for patients with a rare inherited eye disease. (Source: CNN.com - Health)
Source: CNN.com - Health - December 20, 2017 Category: Consumer Health News Source Type: news

Price of world’s first potential $1m drug under scrutiny
Spark Therapeutics set to fuel debate over costs with gene therapy for blindness (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - December 20, 2017 Category: Pharmaceuticals Source Type: news

FDA approves gene therapy to fix mutations that can lead to blindness
In a decision that accelerates a new era for gene therapy, the Food and Drug Administration on Tuesdayapproved a DNA-altering medication that can reverse an inherited form of progressive blindness.The FDA ’s blessing makes Luxturna, a treatment for retinal dystrophy caused by a specific genetic... (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - December 20, 2017 Category: Science Authors: Melissa Healy Source Type: news

FDA Approves Luxturna (voretigene neparvovec-rzyl) Gene Therapy to Treat Patients with a Rare Form of Inherited Vision Loss
December 19, 2017 -- The U.S. Food and Drug Administration today approved Luxturna (voretigene neparvovec-rzyl), a new gene therapy, to treat children and adult patients with an inherited form of vision loss that may result in blindness. Luxturna is... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 19, 2017 Category: Drugs & Pharmacology Source Type: news

Gene Therapy Approved for Rare Inherited Vision-Loss Disorders
Source: HealthDay Related MedlinePlus Pages: Genes and Gene Therapy, Vision Impairment and Blindness (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - December 19, 2017 Category: Consumer Health News Source Type: news

FDA OKs Gene Therapy for Rare Form of Blindness
It's the first gene therapy approved in the United States for a disease caused by mutations in a specific gene, and only the third gene therapy ever approved. (Source: WebMD Health)
Source: WebMD Health - December 19, 2017 Category: Consumer Health News Source Type: news

U.S. approves first gene therapy for inherited disease
(Reuters) - The U.S. Food and Drug Administration on Tuesday approved Spark Therapeutics Inc's treatment for a rare form of blindness, marking the first time the agency has approved a gene therapy for an inherited disease. (Source: Reuters: Health)
Source: Reuters: Health - December 19, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves Gene Therapy for Rare Form of Blindness
Source: HealthDay Related MedlinePlus Pages: Genes and Gene Therapy, Vision Impairment and Blindness (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - December 19, 2017 Category: Consumer Health News Source Type: news

FDA Approves Novel Gene Therapy for Rare Form of Vision Loss FDA Approves Novel Gene Therapy for Rare Form of Vision Loss
Luxturna is for children and adults with a form of inherited vision loss that may lead to blindness. It is the first gene therapy approved in the United States to treat a disease caused by mutations in a specific gene.FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 19, 2017 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news

FDA approves Spark Therapeutics' gene therapy treatment; pricing questions remain
The Food and Drug Administration has approved Luxturna, a new gene therapy developed by Philadelphia-based Spark Therapeutics to treat children and adult patients with an inherited form of vision loss that may result in blindness. Luxturna becomes the first directly administered gene therapy approved in the United States that targets a disease caused by mutations in a specific gene. The big question now becomes what Spark will charge for the gene therapy, administered just once, that analysts… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 19, 2017 Category: Pharmaceuticals Authors: John George Source Type: news

FDA approval for gene therapy marks new era
Spark Therapeutics gets green light in US for blindness treatment that could cost $1m (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - December 19, 2017 Category: Pharmaceuticals Source Type: news